We also evaluated EGFR and AKT signaling, as HUNK has been previously implicated in both of these signaling pathways and the activity of those proteins are often deregulated in HER2-inhibitor resistant breast cancers[19, 20]. This evidence concerns the gene AKT1 and breast carcinoma.